Allogene Therapeutics (ALLO) Common Equity (2019 - 2025)
Historic Common Equity for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $315.3 million.
- Allogene Therapeutics' Common Equity fell 3200.42% to $315.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $315.3 million, marking a year-over-year decrease of 3200.42%. This contributed to the annual value of $422.2 million for FY2024, which is 1758.07% down from last year.
- Latest data reveals that Allogene Therapeutics reported Common Equity of $315.3 million as of Q3 2025, which was down 3200.42% from $344.6 million recorded in Q2 2025.
- In the past 5 years, Allogene Therapeutics' Common Equity registered a high of $1.1 billion during Q1 2021, and its lowest value of $315.3 million during Q3 2025.
- In the last 5 years, Allogene Therapeutics' Common Equity had a median value of $592.0 million in 2023 and averaged $646.6 million.
- Its Common Equity has fluctuated over the past 5 years, first surged by 7638.01% in 2021, then crashed by 3309.99% in 2025.
- Over the past 5 years, Allogene Therapeutics' Common Equity (Quarter) stood at $925.2 million in 2021, then decreased by 27.92% to $666.9 million in 2022, then decreased by 23.19% to $512.2 million in 2023, then fell by 17.58% to $422.2 million in 2024, then dropped by 25.31% to $315.3 million in 2025.
- Its Common Equity stands at $315.3 million for Q3 2025, versus $344.6 million for Q2 2025 and $385.4 million for Q1 2025.